Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$1.17	$1.31	$0.77 ▼ $2.63	$97.94M	1.05	1.34 million shs	1.35 million shs
HLS HLS Therapeutics	C$5.22 -0.8%	C$4.96	C$3.00 ▼ C$5.48	C$116.13M	1.07	12,564 shs	10,115 shs
LABS MediPharm Labs	C$0.08	C$0.07	C$0.06 ▼ C$0.12	C$31.13M	0.88	303,715 shs	102,056 shs
RX BioSyent	C$12.01 +3.6%	C$11.58	C$9.20 ▼ C$12.40	C$137.36M	0.93	4,122 shs	16,054 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	0.00%	-10.69%	-18.75%	+6.36%	-42.65%
HLS HLS Therapeutics	-0.76%	+2.96%	+5.67%	+11.54%	+61.61%
LABS MediPharm Labs	0.00%	-6.25%	+7.14%	0.00%	+7.14%
RX BioSyent	+3.62%	+5.35%	+3.98%	+0.50%	+21.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDL Cardiol Therapeutics	2.5604 of 5 stars	3.7	2.0	0.0	0.0	3.9	0.0	0.6
HLS HLS Therapeutics	1.0111 of 5 stars	1.0	0.0	1.7	0.0	2.9	3.3	0.0
LABS MediPharm Labs	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RX BioSyent	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	583.76% Upside
HLS HLS Therapeutics	2.00	Hold	C$5.00	-4.21% Downside
LABS MediPharm Labs	0.00	N/A	N/A	N/A
RX BioSyent	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LABS, CRDL, RX, and HLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/21/2025	HLS HLS Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy	C$5.00 ➝ C$6.00
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.10 per share	N/A
HLS HLS Therapeutics	C$40.13M	2.89	C$0.34 per share	15.22	C$2.51 per share	2.08
LABS MediPharm Labs	C$39.42M	0.79	C$0.06 per share	1.30	C$0.11 per share	0.68
RX BioSyent	C$34.06M	4.03	C$3.91 per share	3.07	C$3.22 per share	3.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-232.26%	-158.19%	N/A
HLS HLS Therapeutics	-C$15.53M	-C$1.00	N/A	∞	N/A	-38.70%	-25.27%	-2.89%	N/A
LABS MediPharm Labs	-C$12.05M	-C$0.03	N/A	∞	N/A	-30.56%	-24.41%	-7.17%	N/A
RX BioSyent	C$7.02M	C$0.62	19.49	∞	N/A	20.60%	20.01%	12.86%	N/A

Latest LABS, CRDL, RX, and HLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	CRDL Cardiol Therapeutics	-$0.11	-$0.07	+$0.04	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
HLS HLS Therapeutics	C$0.20	3.83%	N/A	N/A	N/A
LABS MediPharm Labs	N/A	N/A	N/A	N/A	N/A
RX BioSyent	C$0.18	1.50%	N/A	29.21%	N/A

Latest LABS, CRDL, RX, and HLS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/21/2025	RX BioSyent	quarterly	C$0.05	1.73%		8/29/2025	9/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDL Cardiol Therapeutics	0.01	2.46	3.26
HLS HLS Therapeutics	86.50	1.56	1.01
LABS MediPharm Labs	1.45	3.21	3.10
RX BioSyent	2.90	3.92	6.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDL Cardiol Therapeutics	12.49%
HLS HLS Therapeutics	65.20%
LABS MediPharm Labs	0.71%
RX BioSyent	1.37%

Insider Ownership

Company	Insider Ownership
CRDL Cardiol Therapeutics	5.25%
HLS HLS Therapeutics	0.37%
LABS MediPharm Labs	4.45%
RX BioSyent	33.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDL Cardiol Therapeutics	20	83.71 million	79.32 million	Not Optionable
HLS HLS Therapeutics	91	22.25 million	N/A	Not Optionable
LABS MediPharm Labs	130	415.00 million	N/A	Not Optionable
RX BioSyent	N/A	11.44 million	N/A	Not Optionable

LABS, CRDL, RX, and HLS Headlines

Recent News About These Companies

BioSyent Declares Third Quarter 2025 Dividend - The Manila Times

August 22 at 12:25 AM | manilatimes.netM

BioSyent Declares Third Quarter 2025 Dividend - The Spec

August 22 at 12:25 AM | thespec.comT

BioSyent Declares Consistent Q3 2025 Dividend

August 22 at 9:20 AM | msn.com

BioSyent Inc. Reports Robust Growth in Q2 and H1 2025 Financial Results

August 22 at 9:20 AM | msn.com

BioSyent Declares Third Quarter 2025 Dividend

August 21 at 5:11 PM | financialpost.comF

BioSyent Releases Financial Results for Q2 and H1 2025

August 21 at 5:11 PM | financialpost.comF

BioSyent (CVE:RX) Shares Cross Below 50-Day Moving Average - Should You Sell?

August 17, 2025 | marketbeat.com

BioSyent to Announce Q2 and H1 2025 Financial Results

August 14, 2025 | msn.com

BioSyent (CVE:RX) Share Price Passes Below Fifty Day Moving Average - Time to Sell?

July 26, 2025 | marketbeat.com

Biosyent Inc. Stock Price History

June 19, 2025 | investing.com

BioSyent (CVE:RX) Has Announced A Dividend Of CA$0.05

May 19, 2025 | finance.yahoo.com

Here's Why We Think BioSyent (CVE:RX) Is Well Worth Watching

May 15, 2025 | finance.yahoo.com

Could The Market Be Wrong About BioSyent Inc. (CVE:RX) Given Its Attractive Financial Prospects?

April 18, 2025 | finance.yahoo.com

FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive Year

April 1, 2025 | markets.businessinsider.com

FAX Capital Corp. Sells 112,400 Shares of BioSyent Inc. (CVE:RX) Stock

December 24, 2024 | insidertrades.com

Investing in BioSyent (CVE:RX) five years ago would have delivered you a 110% gain

December 15, 2024 | uk.finance.yahoo.com

BioSyent Inc. (CVE:RX) Senior Officer Sells C$55,628.75 in Stock

December 13, 2024 | insidertrades.com

Insider Selling: BioSyent Inc. (CVE:RX) Insider Sells 65,000 Shares of Stock

November 27, 2024 | insidertrades.com

BioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 230,800 Shares

November 26, 2024 | insidertrades.com

BioSyent Inc. (RX.V)

November 24, 2024 | finance.yahoo.com

BioSyent Inc. (CVE:RX) Will Pay A CA$0.045 Dividend In Four Days

November 24, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LABS, CRDL, RX, and HLS Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

$1.17 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.17 0.00 (-0.09%)

As of 08/22/2025 07:56 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

HLS Therapeutics TSE:HLS

C$5.22 -0.04 (-0.76%)

As of 08/22/2025 03:59 PM Eastern

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.

MediPharm Labs TSE:LABS

C$0.08 0.00 (0.00%)

As of 08/22/2025 03:59 PM Eastern

MediPharm Labs Corp, along with its subsidiaries, produces purified, pharmaceutical-like cannabis extracts and related derivative products. The company generates revenue from Private label, White label, the Tolling process, and others. Some of its vape brands are Northern Lights, Blue Dream Pink Kush and GG4. Its geographical segments are Canada and Australia.

BioSyent CVE:RX

C$12.01 +0.42 (+3.62%)

As of 08/22/2025 03:59 PM Eastern

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time